Takehito Shukuya

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14

The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer

Hirotsugu Kenmotsu, Tateaki Naito, Madoka Kimura et al. · Journal of Thoracic Oncology · 2011 · 228 citations · Full text

Medicine, Oncology, Pharmacology +16

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

Tateaki Naito, Fumihiro Tanaka, Akira Ono et al. · Journal of Thoracic Oncology · 2012 · 187 citations · Full text

Medicine, Oncology, Chemotherapy +15

Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System

Masahito Hosokawa, Hirotsugu Kenmotsu, Yasuhiro Koh et al. · PLoS ONE · 2013 · 178 citations · Full text

Medicine, Biomedical Engineering, Oncology +13

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori et al. · Journal of Thoracic Oncology · 2022 · 158 citations

Medicine, Oncology, Pharmacotherapy +8